Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.

Biotech SG&A: Viking vs. Soleno's Financial Strategies

__timestampSoleno Therapeutics, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 201429175131244910
Thursday, January 1, 201578782915029636
Friday, January 1, 201683667944846776
Sunday, January 1, 201766103815329003
Monday, January 1, 201865560007121000
Tuesday, January 1, 201969300009128000
Wednesday, January 1, 2020875800010731000
Friday, January 1, 20211080600010701000
Saturday, January 1, 2022984400016121000
Sunday, January 1, 20231348100037021000
Loading chart...

Unveiling the hidden dimensions of data

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Viking Therapeutics, Inc. and Soleno Therapeutics, Inc. have demonstrated distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viking Therapeutics saw a staggering 2,870% increase in SG&A expenses, peaking at $37 million in 2023. This reflects their aggressive expansion and investment in growth. In contrast, Soleno Therapeutics experienced a more modest 360% rise, reaching $13 million in the same year. This suggests a more conservative approach, possibly focusing on sustainable growth. The data highlights the diverse strategies within the biotech sector, where companies balance between innovation and financial prudence. As the industry evolves, these insights offer a glimpse into the financial dynamics shaping the future of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025